We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01020877
Recruitment Status : Completed
First Posted : November 26, 2009
Results First Posted : March 23, 2010
Last Update Posted : June 29, 2010
Information provided by:
Teva Pharmaceuticals USA

Brief Summary:
The primary object of this study was to evaluate the relative bioavailability of the test formulation of metronidazole vaginal gel with the already marketed reference formulation MetroGel-Vaginal Gel® in healthy adult female subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: Metronidazole Phase 1

Detailed Description:

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Study to Evaluate the Relative Bioavailability of Two Metronidazole Vaginal Gel Formulations
Study Start Date : November 2001
Actual Primary Completion Date : November 2001
Actual Study Completion Date : January 2002

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Metronidazole Vaginal Gel
Drug: Metronidazole
Vaginal Gel, 0.75%

Active Comparator: 2
Drug: Metronidazole
Vaginal Gel, 0.75%
Other Name: MetroGel-Vaginal®

Primary Outcome Measures :
  1. Cmax (Maximum Observed Concentration of Drug Substance in Plasma) [ Time Frame: Blood samples collected over a 60 hour period. ]
    Bioequivalence based on Cmax.

  2. AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) [ Time Frame: Blood samples collected over a 60 hour period. ]
    Bioequivalence based on AUC0-t.

  3. AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) [ Time Frame: Blood samples collected over a 60 hour period. ]
    Bioequivalence based on AUC0-inf.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Females, 18 years of age or older.
  • Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
  • Signed informed consent form, which meets all criteria of current FDA regulations.
  • If female and of child bearing potential prepared to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g. condom, IUD, oral or implanted hormonal contraceptives).
  • Weight within + 25% from normal for height and weight for body frame as described in Novum Standard Operating Procedures adapted from the "MetLife® Height and Weight Tablets", Copyright© 1993.

Exclusion Criteria:

  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • History of allergy or sensitivity to metronidazole, or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  • Significant history or current evidence of chronic infectious disease, system disorder or organ disorder.
  • History of psychiatric disorders occurring within the last two years that required hospitalization or medication.
  • Presence of a medical condition requiring regular treatment with prescription drugs (other than contraceptives or hormonal replacement therapy).
  • Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing.
  • Receipt of any drug as part of a research study within 30 days prior to dosing.
  • Drug or alcohol addiction requiring treatment in the past 12 months.
  • Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days prior to dosing.
  • Positive test for HIV, Hepatitis B surface antigen or Hepatitis C antibody.
  • Positive test results for drugs of abuse at screening.
  • Evidence of vulvovaginitis or cervicitis (e.g. Bacterial vaginosis, vaginal candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhea, or history of Herpes simplex or human papillomavirus).
  • Vulvar or vaginal conditions that may affect absorption of the drug.
  • Clinically significant abnormal findings on PAP smear within previous 12 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01020877

Layout table for location information
United States, Pennsylvania
Novum Pharmaceutical Research Services
Pittsburgh, Pennsylvania, United States, 15206
Sponsors and Collaborators
Teva Pharmaceuticals USA
Layout table for investigator information
Principal Investigator: Shirley A Kennedy, MD Novum Pharmaceutical Research Services
Layout table for additonal information
Responsible Party: Associate Director, Biopharmaceutics, Teva Pharmaceuticals USA
ClinicalTrials.gov Identifier: NCT01020877    
Other Study ID Numbers: 10136019
First Posted: November 26, 2009    Key Record Dates
Results First Posted: March 23, 2010
Last Update Posted: June 29, 2010
Last Verified: June 2010
Keywords provided by Teva Pharmaceuticals USA:
Healthy Subjects
Healthy, Normal Subjects
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Infective Agents
Anti-Bacterial Agents
Antiprotozoal Agents
Antiparasitic Agents